US FDA Clearance For Masimo’s Stork Wakes Up OTC Baby Monitoring Technology Competition

Masimo receives US regulatory clearance for Stork OTC baby monitoring system six months after Owlet received first clearance for its Dream Sock following a regulatory stumble which halted sales of a previous device, Smart Sock, in 2021.

• Source: Shutterstock

Masimo Corp. has received US regulatory clearance for its Stork OTC baby monitoring system six months after a competitor pioneered the market following its regulatory stumble which halted sales of a previous device in 2021.

More from Business

End Of Year Recovery Ensures Recordati’s OTC Business Keeps Growing

 
• By 

Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.

Alfasigma Seeking Slice Of EU’s Largest OTC Market With German Launch

 
• By 

Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.

People On The Move: Appointments At PAGB, Activ’Inside, EMA

 
• By 

Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.

Over The Counter: What To Expect From The 61st AESGP Annual Meeting, With Jurate Švarcaite

 
• By 

HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.

More from Health

People On The Move: Appointments At Pharma Deutschland, MHRA, Futura

 
• By 

A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.

Marketplace Results After FDA OTC Monograph Overhaul Rely On OMUFA Reauthorization

 

“If this doesn’t get reauthorized, look at the number of the ingredients out there, the number of products, what would happen all those products out there for the consumer, on that shelf, in the drugstore or someplace?” says Rep. Bob Latta during House hearing.

Democrats Torch Trump’s HHS Layoffs During House Hearing On OMUFA Reauthorization

 

Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. “If we reauthorize it, will it continue?” Texas representative Lizzie Fletcher asks of OMUFA.